Skip to content
Screener

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
59.5M+2.7%
Nuvation Bio logo
Nuvation BioNUVB
348.8M+2.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
61.3M+8.9%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
100.6M+12.8%
Opko Health logo
Opko HealthOPK
755.3M-4.2%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Provision for income taxes3,00365
Net income$8,654$11,446
Net income per share
Basic$0.47$0.64
Diluted$0.44$0.63
Weighted average shares used in computing net income per share
Basic18,41217,808
Diluted19,68618,169

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's shares (diluted)?
Rigel Pharmaceuticals (RIGL) reported shares (diluted) of 19.7M in Q1 2026.
How has Rigel Pharmaceuticals's shares (diluted) changed year-over-year?
Rigel Pharmaceuticals's shares (diluted) increased by 8.3% year-over-year, from 18.2M to 19.7M.
What is the long-term trend for Rigel Pharmaceuticals's shares (diluted)?
Over 4 years (2021 to 2025), Rigel Pharmaceuticals's shares (diluted) has grown at a -42.7% compound annual growth rate (CAGR), from 687.6M to 74.3M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Rigel Pharmaceuticals's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude